Clinical trial
Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With…
NCT00100672 · INSYS Therapeutics Inc, Industry · Completed
Key facts
| NCT number | NCT00100672 |
|---|---|
| Title | Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer |
| Official title | Phase I Study of an Easy-to-Use Intravenous Formulation of Liposome Entrapped C-raf Antisense Oligonucleotide (LErafAON-ETU) Administered on a Weekly Schedule in Patients With Advanced Cancer |
| Lead sponsor | INSYS Therapeutics Inc, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | LErafAON-ETU |
| Enrollment | 40 |
| Start date | Dec 1, 2004 |
| Primary completion | Oct 1, 2009 |
| Completion | Nov 1, 2010 |
| First posted | Jan 5, 2005 |
| Last update posted | Jul 4, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: